Form 4: Guardant Health Chief Legal Officer Reports Routine Stock Vesting and Tax-Related Share Disposal

Guardant Health's Chief Legal Officer, John G. Saia, reported the vesting of restricted stock units and a corresponding disposal of shares to cover tax withholding obligations.

Summary

• John G. Saia, Chief Legal Officer of Guardant Health, Inc. (GH), reported transactions on July 1, 2025.
• Saia acquired 974 shares of Common Stock through the vesting of restricted stock units (RSUs) at a price of $0.00 per share.
• Additionally, Saia acquired 1,667 shares of Common Stock through the vesting of another restricted stock unit award at a price of $0.00 per share.
• To cover tax withholding obligations related to the RSU vesting, 1,386 shares of Common Stock were disposed of at a price of $50.71 per share.
• Following these transactions, John G. Saia directly beneficially owns 44,823 shares of Common Stock.
• The vested RSUs include an award granted on November 7, 2022, with 25% vesting on October 1, 2023, and the remainder vesting quarterly over three years.
• Another RSU award granted on December 13, 2023, had 33% vest on October 1, 2024, with the remaining 67% vesting quarterly over two years.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to equity compensation vesting and tax withholding, which is a neutral event and does not indicate significant positive or negative sentiment regarding the company's performance or outlook.

Positives

• John G. Saia, Chief Legal Officer, acquired a total of 2,641 shares of Common Stock through the vesting of restricted stock units, indicating continued equity participation in Guardant Health.
• The vesting of restricted stock units represents a realization of compensation for the Chief Legal Officer.

Negatives

• 1,386 shares of Common Stock were disposed of at $50.71 per share to cover tax withholding obligations, reducing the direct beneficial ownership of the Chief Legal Officer.

Future Outlook

The remaining 75% of the November 7, 2022 RSU award will vest in equal quarterly installments over the remaining three-year period after October 1, 2023. The remaining 67% of the December 13, 2023 RSU award will vest in equal quarterly installments over the remaining two-year period after October 1, 2024.

Industry Context

This filing is a routine disclosure of insider stock transactions, specifically related to equity compensation vesting. It does not provide broader industry trends or competitive analysis. Such transactions are common across all industries for publicly traded companies that use equity-based compensation.

Stakeholder Impact

• Shareholders: The disposal of shares for tax withholding slightly dilutes ownership but is a common practice. The vesting of RSUs aligns management's interests with shareholders.
• Employees: The report highlights the company's use of equity compensation, which is a common incentive for key personnel.

Next Steps

• Remaining portions of the November 7, 2022 RSU award are scheduled to vest in equal quarterly installments over the remaining three-year period after October 1, 2023.
• Remaining portions of the December 13, 2023 RSU award are scheduled to vest in equal quarterly installments over the remaining two-year period after October 1, 2024.

Key Dates

Keywords

Guardant Health, GH, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, John G. Saia, Chief Legal Officer, Equity Compensation